SCHEMBL68995

SCHEMBL68995

O=C(O)c1cccc2nc3c(C(=O)O)cccc3nc12

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.88
ALOX15 P16050 2/20 0.50
NR4A1 P22736 1/20 0.48
NR4A2 P43354 1/20 0.48
NR4A3 Q92570 1/20 0.48
ACHE P22303 1/20 0.48
KDM4E B2RXH2 4/20 0.47
RAB9A P51151 2/20 0.47
HSD17B10 Q99714 1/20 0.47
MAPT P10636 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GAA P10253 2/20 0.46
KMT2A Q03164 2/20 0.46
ATM Q13315 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
DHODH Q02127 2/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30548734 1.00 ALDH1A1 (0.88) ALDH1A1ALOX15NR4A1NR4A2NR4A3
Phenazine-1-Carboxylic Acid SCHEMBL27884214 0.94 ALDH1A1 (1.00) ALDH1A1ALOX15NR4A1NR4A2NR4A3
Phenazine-1-Carboxylic Acid SCHEMBL28160016 0.94 ALDH1A1 (1.00) ALDH1A1ALOX15NR4A1NR4A2NR4A3
Phenazine-1-Carboxylic Acid SCHEMBL29370801 0.94 ALDH1A1 (1.00) ALDH1A1ALOX15NR4A1NR4A2NR4A3
Phenazine-1-Carboxylic Acid SCHEMBL122864 0.94 ALDH1A1 (1.00) ALDH1A1ALOX15NR4A1NR4A2NR4A3
Phenazine-1-Carboxylic Acid SCHEMBL28714733 0.92 ALDH1A1 (0.96) ALDH1A1ALOX15NR4A1NR4A2NR4A3
SCHEMBL19971558 0.90 ALDH1A1 (0.73) ALDH1A1ALOX15NR4A1NR4A2NR4A3
Phenazine-1-Carboxylic Acid SCHEMBL27752237 0.90 ALDH1A1 (0.93) ALDH1A1ALOX15NR4A1NR4A2NR4A3
SCHEMBL3193693 0.90 ALDH1A1 (0.73) ALDH1A1ACHEKDM4ERAB9AMAPT
SCHEMBL5448034 0.89 ALDH1A1 (0.71) ALDH1A1KDM4ERAB9AHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117778280-A Chassis strain suitable for heterologous biosynthesis of antibacterial material myxin, construction method and application thereof 江苏省农业科学院 2024-03-29 CN claimed
CN-116656713-A Application of phzB-G gene in synthesis of phenazine-1, 6-dicarboxylic acid 上海交通大学 2023-08-29 CN claimed
US-20190048354-A1 PATHWAY INTEGRATION AND EXPRESSION IN HOST CELLS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-02-14 US claimed
WO-2017176347-A9 PATHWAY INTEGRATION AND EXPRESSION IN HOST CELLS THE REGENTS OF THE UNIVERSITY OF CALIFORINIA (US) 2017-11-09 WO claimed
WO-2017176347-A2 PATHWAY INTEGRATION AND EXPRESSION IN HOST CELLS THE REGENTS OF THE UNIVERSITY OF CALIFORINIA (US) 2017-10-12 WO claimed
EP-4022047-B1 IMPROVED POLYPEPTIDES CAPABLE OF CONVERTING SUBSTRATE 3-KETO- DEOXYNIVALENOL INTO 3-EPI- DEOXYNIVALENOL DSM Austria GmbH (AT) 2026-04-22 EP disclosed
EP-4631530-A1 STERILIZATION METHOD AND COMPOSITION USED IN STERILIZATION METHOD National Institute for Materials Science (JP) 2025-10-15 EP disclosed
US-20250228880-A1 REDOX-ACTIVE COMPOUNDS AND RELATED COMPOUNDS, COMPOSITIONS, METHODS AND SYSTEMS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2025-07-17 US disclosed
EP-3273802-B1 USE OF A TRICHOTHECENE-TRANSFORMING ALCOHOL DEHYDROGENASE, METHOD FOR TRANSFORMING TRICHOTHECENES AND TRICHOTHECENE-TRANSFORMING ADDITIVE DSM Austria GmbH (AT) 2025-06-25 EP disclosed
CN-112442489-B Improved polypeptides for converting substrate 3-keto-deoxynivalenol to 3-epi-deoxynivalenol 爱尔伯股份公司 2025-02-25 CN disclosed
CN-117778280-A Chassis strain suitable for heterologous biosynthesis of antibacterial material myxin, construction method and application thereof 江苏省农业科学院 2024-03-29 CN disclosed
US-11820973-B2 Methods and system for interfering with viability of bacteria and related compounds and compositions CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2023-11-21 US disclosed
US-5723759-A ANTIPATHOGENIC SUBSTANCE NOVARTIS FINANCE CORPORATION (US) 1998-03-03 US disclosed
US-5698425-A TRANSFORMING PLANT TO PRODUCE PYRROLNITRIN NOVARTIS FINANCE CORPORATION (US) 1997-12-16 US disclosed
US-5679560-A ENZYME REQUIRED IN BIOSYNTHETIC PATHWAY OF PYRROLNITRIN; PROTECTION OF PLANTS AGAINST PHYTOPATHOGENS NOVARTIS FINANCE CORPORATION (US) 1997-10-21 US disclosed
US-5662898-A Genes for the synthesis of antipathogenic substances CIBA-GEIGY CORPORATION (US) 1997-09-02 US disclosed
US-5643774-A DNA MOLECULES WITH POLYPEPTIDES FORMED BY BIOSYNTHESIS CIBA-GEIGY CORPORATION (US) 1997-07-01 US disclosed
US-5639949-A DNA MOLECULE ENCODING ONE OR MORE POLYPEPTIDES REQUIRED FOR THE BIOSYNTHESIS OF PYRROLNITRIN CIBA-GEIGY CORPORATION (US) 1997-06-17 US disclosed
EP-0759078-A1 GENES FOR THE SYNTHESIS OF ANTIPATHOGENIC SUBSTANCES Novartis AG (CH) 1997-02-26 EP disclosed
WO-1995033818-A2 GENES FOR THE SYNTHESIS OF ANTIPATHOGENIC SUBSTANCES CIBA-GEIGY AG (CH) 1995-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250228880-A1 REDOX-ACTIVE COMPOUNDS AND RELATED COMPOUNDS, COMPOSITIONS, METHODS AND SYSTEMS TXN2, SQOR, LPO ALDH1A1 720/4885ALOX15 257/4885NR4A1 2853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.